1. Home
  2. LMND vs TGTX Comparison

LMND vs TGTX Comparison

Compare LMND & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lemonade Inc.

LMND

Lemonade Inc.

HOLD

Current Price

$75.76

Market Cap

6.0B

Sector

Finance

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$30.81

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LMND
TGTX
Founded
2015
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
5.5B
IPO Year
2020
1995

Fundamental Metrics

Financial Performance
Metric
LMND
TGTX
Price
$75.76
$30.81
Analyst Decision
Hold
Strong Buy
Analyst Count
8
4
Target Price
$48.25
$54.75
AVG Volume (30 Days)
2.3M
1.4M
Earning Date
11-05-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.78
Revenue
$658,300,000.00
$531,898,000.00
Revenue This Year
$40.13
$87.88
Revenue Next Year
$59.80
$48.75
P/E Ratio
N/A
$11.08
Revenue Growth
33.66
100.88
52 Week Low
$24.31
$25.28
52 Week High
$85.20
$46.48

Technical Indicators

Market Signals
Indicator
LMND
TGTX
Relative Strength Index (RSI) 49.52 46.32
Support Level $80.22 $29.79
Resistance Level $84.84 $31.37
Average True Range (ATR) 5.40 1.00
MACD -0.71 0.04
Stochastic Oscillator 19.36 47.47

Price Performance

Historical Comparison
LMND
TGTX

About LMND Lemonade Inc.

Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes. The company is using technology, data, artificial intelligence, contemporary design, and social impact to deliver delightful and affordable insurances. Geographically, it operates in California, Texas, New York, New Jersey, Illinois, Georgia, Washington, Colorado, Pennsylvania, Oregon and others.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: